Company / PP&E (Net)
Syndax Pharmaceuticals Inc PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$181.0K
FY2025
5-year range
$0 / $278.0K
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#180 of 193
Health Care
What the data says
Among 193 Health Care companies, Syndax Pharmaceuticals Inc is in the bottom 7% for pp&e (net). PP&E (Net) returned to growth in FY2025 after 3 years of decline, reaching $181,000.
Based on SEC 10-K filings.
$181,000 in FY2025 with a 5-year CAGR of -1.2%.
Improved from $8,000 to $181,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +108.4%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 193This company $181.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.2%, indicating a declining trend.
- Ranks #180 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2018.
- Lowest pp&e (net) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $181.0K | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $8.0K | -60.0% |
| FY2022 | $20.0K | -92.8% |
| FY2021 | $278.0K | +44.8% |
| FY2020 | $192.0K | -31.7% |
| FY2019 | $281.0K | -24.7% |
| FY2018 | $373.0K | +39.7% |
| FY2017 | $267.0K | +2.7% |
| FY2016 | $260.0K | +195.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026